THC-306 (foresiGHt)

A multicenter, randomized, parallel-arm, placebo-controlled (double-blind) and active controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily somatropin product in adults with growth hormone deficiency.

Purpose

Primary objective is to evaluate the efficacy of once-weekly lonapegsomatropin compared to placebo at 38 weeks in adults with Growth Hormone Deficiency (GHD). Subject population will consist of Adults with GHD (male and female), either treatment-naïve or not having received GH therapy for at least 12 months prior to screening will be enrolled.